Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ADVENTRX Pharmaceuticals has entered into a multi-year agreement with Patheon to manufacture ANX-188 drug product.
Subscribe to our email newsletter
Under the agreement, Patheon will formulate, fill and finish ANX-188 drug product for use in clinical trials, including the Phase 3 study of ANX-188 that ADVENTRX plans to initiate in 2012.
ADVENTRX chief executive officer Brian Culley said the agreement is another step toward initiating the Phase 3 study of ANX-188 in patients with sickle cell disease.
"Patheon is a global contract manufacturer that serves more than 300 customers, including many of the world’s largest pharmaceutical and biotechnology companies," Culley added.